Core Insights - Genenta Science held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024, where shareholders approved the appointment of five directors to the Board, including four new members [1][2] - The new Board members are John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D., and Todd Wider, M.D., with Pierluigi Paracchi continuing as Chairman [1][2] Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing a cell-based platform utilizing hematopoietic stem cells for safe and durable treatments of solid tumors [1][7] - The company's proprietary therapy, Temferon™, is designed to deliver immunomodulatory molecules directly to tumors and is currently under investigation in a phase 1/2a clinical trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter [8] New Board Members' Backgrounds - John L. Cantello, Ph.D., has over 20 years of experience in the biopharma industry, previously serving as VP and Head of Business Development at GlaxoSmithKline and AstraZeneca, with a track record of closing deals exceeding $30 billion [3] - Lauren H. Chung, Ph.D., has extensive experience in investment management strategies in healthcare, having founded Minleigh LLC and co-founded Tokum Capital Management, with a strong academic background [4] - Armon R. Sharei, Ph.D., is the founder and CEO of Portal Bio and has a history of leading companies through significant financing and clinical trials, with a Ph.D. from MIT [5] - Todd Wider, M.D., has consulted for various biotechnology entities and has a notable academic background, including being a co-founder of Xanadu Bio and serving on multiple boards [6]
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider